Leif W Ellisen

25PUBLICATIONS
101CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersLiquid biopsiesCancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (25)

|Jun 17, 2026
Dynamic monitoring of antibody drug conjugates targeting TROP2 or HER2 in breast cancer using circulating tumor cells.

|Jan 31, 2025
CREB1-BCL2 drives mitochondrial resilience in RAS GAP-dependent breast cancer chemoresistance.

Ki-Fong Man, Omeed Darweesh, Jinghui Hong

|Jan 08, 2025
Adjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitor, ribociclib, for localized hormone receptor-positive/HER2- breast cancer (LEADER).

Laura M Spring, Lauren Scarpetti, Arielle J Medford

|Jan 02, 2025
TOP1 Mutations and Cross-Resistance to Antibody-Drug Conjugates in Patients with Metastatic Breast Cancer.

Rachel O Abelman, Bogang Wu, Haley Barnes

|May 06, 2024
Antibody-Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer.

Aditya Bardia, Sheng Sun, Nayana Thimmiah

|Apr 11, 2024
Genomic spectrum of actionable alterations in serial cell free DNA (cfDNA) analysis of patients with metastatic breast cancer.

Yael Bar, Jennifer C Keenan, Andrzej Niemierko

Pageof 5

Frequent Collaborators

12 joint publications

Steven J Isakoff

6 joint publications

Dejan Juric

6 joint publications

Laura Spring

6 joint publications

Siang-Boon Koh